The short answer
Magnesium hydroxide accelerated glipizide’s early absorption and glucose effect in a small study. Total drug exposure did not increase, and the findings do not establish the risk with extended-release glipizide.
What this answer covers
Oral magnesium hydroxide antacid with single-dose conventional glipizide; not all magnesium salts, magnesium deficiency treatment or extended-release products.
- Supplement or preparation
- Magnesium hydroxide
- Medication ingredient
- glipizide
What the direct study found
Eight fasting healthy volunteers received glipizide with magnesium hydroxide or water. More glipizide reached the bloodstream early when magnesium hydroxide was used, with a larger early insulin response and glucose decline.
Early exposure differs from total exposure
The total drug exposure, peak concentration and elimination half-life were unchanged. The result supports faster early absorption, not a general claim of greater total absorption or persistently higher levels.
Formulation and setting limit the result
This was a single-dose study in healthy people, not long-term treatment in diabetes. It does not supply a clinical hypoglycemia rate. Glipizide extended-release tablets deliver the medicine differently, so the result cannot simply be transferred to them.
Ask about antacid use
Discuss the exact product and amount with the diabetes team before starting or changing it. Follow your established glucose-monitoring and low-glucose treatment plan; do not adjust glipizide yourself. Identify whether the product is magnesium hydroxide and whether glipizide is immediate or extended release. The trial did not establish a protective spacing interval.
Evidence and practical considerations
Side effects & toxicity
Direct early glucose/insulin enhancement supports a conditional hypoglycemia precaution, but no clinical event rate or XL effect established.
- Exact scope
- Oral magnesium hydroxide antacid with single-dose conventional glipizide; not all magnesium salts, magnesium deficiency treatment or extended-release products. with Oral glipizide RxCUI4821 IN, immediate and extended release distinguished.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Exact source preparation, medication and endpoint limits apply; no universal dose change or spacing.
Factors that may matter: Formulation; Dose and duration; Meal pattern; Other glucose-lowering agents; Kidney and liver function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eight healthy volunteers.
Magnesium hydroxide raised early glipizide AUC and early insulin/glucose responses, but peak concentration, total AUC, half-life and time to peak were unchanged.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Eight healthy volunteers; short single-dose study, no reported clinical hypoglycemia incidence or extended-release evaluation.
Research assessment: · Open full citations ↗
Absorption & effectiveness
Supported only as increased early exposure/faster absorption; total AUC and peak concentration were unchanged.
- Exact scope
- Oral magnesium hydroxide antacid with single-dose conventional glipizide; not all magnesium salts, magnesium deficiency treatment or extended-release products. with Oral glipizide RxCUI4821 IN, immediate and extended release distinguished.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Exact source preparation, medication and endpoint limits apply; no universal dose change or spacing.
Factors that may matter: Formulation; Dose and duration; Meal pattern; Other glucose-lowering agents; Kidney and liver function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eight healthy volunteers.
Magnesium hydroxide raised early glipizide AUC and early insulin/glucose responses, but peak concentration, total AUC, half-life and time to peak were unchanged.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Eight healthy volunteers; short single-dose study, no reported clinical hypoglycemia incidence or extended-release evaluation.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact glipizide article preserving formulation, preparation and glucose endpoint distinctions. | |
| Research summary published |
Article revision: 38c4e0b07c4649dd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.